Reports Q4 revenue $82.4M, consensus $79.1M. “Our record fourth quarter results cap off a successful year of global execution and key milestone achievements, leaving us well positioned to execute our strategic plans as we enter into what we believe will be a transformative period for our company over the coming years,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GKOS:
- Glaukos Quarterly Summary: Performance Insights and Disclosures
- GKOS Earnings this Week: How Will it Perform?
- Glaukos backs FY24 revenue view $350M-$360M, consensus $352.71M
- Glaukos raises FY23 revenue view to $313M from $307M-$310M, consensus $309.02M
- Glaukos reports preliminary Q4 revenue $81M, consensus $76.66M
